Role of Lutetium Radioligand Therapy in Prostate Cancer.
Lutetium-177-PSMA
prostate cancer
radiation therapy
radioactive isotopes
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
01 Jul 2024
01 Jul 2024
Historique:
received:
02
06
2024
revised:
24
06
2024
accepted:
26
06
2024
medline:
13
7
2024
pubmed:
13
7
2024
entrez:
13
7
2024
Statut:
epublish
Résumé
Theranostics utilize ligands that chelate radionuclides and selectively bind with cancer-specific membrane antigens. In the case of prostate cancer (PCa), the state-of-the-art lutetium-177-PSMA combines the radioactive β-emitter
Identifiants
pubmed: 39001495
pii: cancers16132433
doi: 10.3390/cancers16132433
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng